Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan
Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan
复制标题
沃诺拉赞治疗有症状的胃食管反流病患者的长期结果
DOI：
10.1080/00365521.2018.1486883
复制
发表时间：
2018
影响因子：
1.9
通讯作者：
H. Yamamoto
中科院分区：
文献类型：
--
作者：
S. Shinozaki;H. Osawa;Yasutoshi Kobayashi;H. Sakamoto;Y. Hayashi;Y. Miura;A. Kawarai Lefor;H. Yamamoto
摘要目的：新型钾竞争性酸阻滞剂沃诺拉赞可提供快速有效的酸抑制作用。本研究的目的是评价沃诺拉赞治疗症状性胃食管反流病（GERD）患者的长期结局。研究方法：这项回顾性队列研究纳入了55例接受沃诺拉赞治疗并随访超过1年的症状性GERD患者。使用Izumo量表（一种反映与各种腹部症状相关的生活质量的自我报告问卷）评价沃诺拉赞对胃肠道症状的有效性。结果：这55例有症状的GERD患者有非糜烂性反流病（n = 30）或糜烂性食管炎（n = 25）。沃诺拉赞（10 mg）治疗1个月可改善89%（应答者）的GERD症状，82%的患者在未接受额外治疗的情况下可维持1年的改善。一年的维持治疗导致47%的GERD症状持续缓解。在49例应答者中，9例患者GERD症状复发，沃诺拉赞剂量递增改善了6例患者的症状。开始沃诺拉赞治疗前的餐后不适和糜烂性食管炎分别被确定为GERD症状持续缓解1年的显著阴性和阳性预测因子。上腹痛、餐后不适、便秘和腹泻在一个月时显著改善，并维持一年。治疗一年后，糜烂性食管炎的内镜治愈率为95%。结论：沃诺拉赞治疗1年可显著改善GERD症状，糜烂性食管炎的内镜愈合令人满意。长期使用沃诺拉赞可有效控制GERD。
Abstract Objective: The novel potassium-competitive acid blocker, vonoprazan, provides rapid and effective acid suppression. The aim of this study is to evaluate the long-term outcomes of patients with symptomatic gastroesophageal reflux disease (GERD) treated with vonoprazan. Methods: This retrospective cohort study included 55 patients with symptomatic GERD treated with vonoprazan who have been followed for more than one year. The effectiveness of vonoprazan on gastrointestinal symptoms was evaluated using the Izumo scale, a self-reported questionnaire reflecting quality of life related to various abdominal symptoms. Results: These 55 patients with symptomatic GERD had non-erosive reflux disease (n = 30) or erosive esophagitis (n = 25). Vonoprazan (10 mg) for one month improved GERD symptoms in 89% (responders) and the improvement was maintained at one year in 82% without additional treatment. One-year maintenance therapy resulted in sustained resolution of GERD symptoms in 47%. Of the 49 responders, nine patients had relapse of GERD symptoms and dose escalation of vonoprazan improved the symptoms in six patients. Postprandial distress and the presence of erosive esophagitis before starting vonoprazan were identified as significant negative and positive predictors of sustained resolution of GERD symptoms for one year, respectively. Epigastric pain, postprandial distress, constipation and diarrhea were significantly improved at one-month and maintained at one year. After one-year of treatment, the endoscopic healing rate of erosive esophagitis was 95%. Conclusion: One-year treatment with vonoprazan significantly improves GERD symptoms and endoscopic healing of erosive esophagitis is satisfactory. The long-term use of vonoprazan is effective and useful to control GERD.
幽门螺杆菌根除治疗对胃癌的影响。
DOI：
--
发表时间：
2020
期刊：
影响因子：
--
作者：
Harada Ibuki;Sasaki Haruka;Murakami Koichi;Nishiyama Akira;Nakabayashi Jun;Ichino Motohide;Miyazaki Takuya;Kumagai Ken;Matsumoto Kenji;Hagihara Maki;Kawase Wataru;Tachibana Takayoshi;Tanaka Masatsugu;Saito Tomoyuki;Kanamori Heiwa;Fujita Hiroyuki;Fujisawa ;Suzuki Hidekazu
通讯作者：
Suzuki Hidekazu
影响因子：
6.3
作者：
Iwakiri, Katsuhiko;Kinoshita, Yoshikazu;Shimosegawa, Tooru
通讯作者：
Shimosegawa, Tooru
影响因子：
7.6
作者：
Miwa, H.;Nakajima, K.;Haruma, K.
通讯作者：
Haruma, K.